Rejuvenate Bio Inc.

Rejuvenate Bio Inc. is a biotechnology company focused on pioneering gene therapy solutions to combat chronic, age-related diseases, enhancing health and quality of life through advanced genetic editing technologies. Founded in 2017 by Daniel Oliver and Noah Davidsohn, Rejuvenate Bio Inc. is headquartered in San Diego, US.

The company specializes in innovative gene therapy targeting chronic diseases. It has completed 2 deals, with its most recent funding round being a Grant of USD 4. 000 mn from the California Institute for Regenerative Medicine on July 1, 2024, bringing the total amount raised to USD 14. 800 mn.

Rejuvenate Bio specializes in innovative gene therapy solutions aimed at addressing chronic, age-related diseases that affect a significant portion of the American population. Their core offerings encompass various human and animal health therapies designed to target the underlying genetic causes of these conditions. The company employs advanced gene editing technologies to develop therapies that not only alleviate symptoms but also aim for long-term health improvements, thereby enhancing the quality of life for individuals suffering from chronic diseases. These products are particularly relevant for healthcare providers seeking effective treatments for patients diagnosed with conditions such as diabetes and cardiovascular diseases.

Rejuvenate Bio's products are marketed primarily within the United States, with potential expansion into international markets as the company grows. Rejuvenate Bio generates revenue through a combination of partnerships and direct sales of its gene therapy products. The company's revenue model includes engaging with healthcare providers and institutions that incorporate its therapies into their treatment protocols. Transactions typically involve negotiated contracts that outline specific pricing structures for different treatment regimens.

The company's flagship products, which are designed to deliver targeted gene therapies, are sold on a per-treatment basis, creating a direct-to-consumer approach as well as B2B transactions with healthcare providers. This dual approach allows Rejuvenate Bio to cater to both individual patients seeking innovative treatments and larger healthcare systems looking to enhance their therapeutic offerings. In July 2024, Rejuvenate Bio, Inc. raised USD 4.

000 mn in grant funding from California Institute for Regenerative Medicine. The company will utilize this funding to complete its IND-enabling activities for the development of RJB-0402, targeting desmoplakin gene variant arrhythmogenic cardiomyopathy (DSP ACM). Through ongoing development and potential product launches, Rejuvenate Bio aims to expand its innovative gene therapies into new markets while strengthening their current offerings.